Trabectedin

FDA Drug Profile — EVDI, YONDELIS

Trabectedin is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand names including EVDI, YONDELIS. Available dosage forms: injection, powder, lyophilized, for solution, powder, injection, solution, concentrate.

Drug details

Generic Name
Trabectedin
Brand Names
EVDI, YONDELIS
Application Number
NDA220837
Sponsor
BSP Pharmaceuticals S.P.A.
NDC Codes
6
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, POWDER, INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
TRABECTEDIN

Indications and Usage

1 INDICATIONS AND USAGE EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.